Display options
Cite
Alphonse J, Bellam S, Fernandez M, et al. The FDA Funding Crisis. J Pharm Technol. 2013;30(2):57-60doi: 10.1177/8755122513505224.
Alphonse, J., Bellam, S., Fernandez, M., Gilbert, A., Roper, L., Zapantis, A., & Speth, R. C. (2014). The FDA Funding Crisis. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 30(2), 57-60. https://doi.org/10.1177/8755122513505224
Alphonse, Judith, et al. "The FDA Funding Crisis." The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians vol. 30,2 (2014): 57-60. doi: https://doi.org/10.1177/8755122513505224
Alphonse J, Bellam S, Fernandez M, Gilbert A, Roper L, Zapantis A, Speth RC. The FDA Funding Crisis. J Pharm Technol. 2014 Apr;30(2):57-60. doi: 10.1177/8755122513505224. Epub 2013 Oct 01. PMID: 34861005; PMCID: PMC6005411.
Copy Download .nbib Format: NLM
Share it on

J Pharm Technol. 2014 Apr;30(2):57-60. doi: 10.1177/8755122513505224. Epub 2013 Oct 01.

The FDA Funding Crisis.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

Judith Alphonse, Sireesha Bellam, Marlene Fernandez, Anishka Gilbert, Lauren Roper, Antonia Zapantis, Robert C Speth

Affiliations

  1. Nova Southeastern University, Fort Lauderdale, FL, USA.
  2. Georgetown University, Washington, DC, USA.

PMID: 34861005 PMCID: PMC6005411 DOI: 10.1177/8755122513505224

Abstract

The role of the Food and Drug Administration (FDA) is to ensure the safety of prescription and nonprescription drugs, dietary supplements, and the food supply, representing more than 20% of US consumer spending. The increased need to monitor imported drugs, drug products and foods, drug shortages, and compounding pharmacies bring the adequacy of FDA funding into question. Performing even at status quo cannot be accomplished if responsibilities increase without equitable funding increases: both from the federal government and fees imposed on FDA-regulated industries. Additionally, scientific advancement, new legislation, and new industries are continually increasing the FDA workload, necessitating commensurate budget increases.

© The Author(s) 2013.

Keywords: FDA; drug compounding; funding; quality control; regulation; safety

Conflict of interest statement

Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

  1. Drug Test Anal. 2011 Nov-Dec;3(11-12):873-6 - PubMed
  2. Clin Pharmacol Ther. 2008 Mar;83(3):494-7 - PubMed
  3. N Engl J Med. 2012 Feb 2;366(5):389-91 - PubMed
  4. JAMA. 1998 May 20;279(19):1571-3 - PubMed
  5. Perfusion. 2013 Jan;28(1):61-5 - PubMed
  6. Am J Health Syst Pharm. 2009 Aug 1;66(15):1399-406 - PubMed
  7. MMWR Morb Mortal Wkly Rep. 2013 May 17;62(19):377-81 - PubMed

Publication Types